

Index

- abdominal pain, CBT as treatment
 for, 333
- acetaminophen, 44–46
 contraindications, 46
 dosage, 45
 indications, 44
 mechanism of action, 44
 metabolism, 46
 routes of administration, 45
 side effects/adverse reactions, 45–46
 as treatment for OA-related
 pain, 167
 as treatment for PDPH, 71
 as treatment for PF, 198
 as treatment for VCF, 111
- Achilles tendinopathy
 diagnosis, 184
 pathophysiology, 183
 risk factors, 182
 treatment, 186
- acupuncture
 comparison with dry needling, 265
 efficacy, 339–341
 MTrPs and, 262
 for neuropathic pain control, 341
 traditional understanding, 338
 as treatment for cancer pain, 312
 as treatment for CPPS, 340
 as treatment for fibromyalgia, 340
 as treatment for LBP, 339
 as treatment for migraine, 341
 as treatment for MPS, 265–266
 as treatment for ON, 89
 as treatment for pregnancy-related
 pain, 340
- adhesive capsulitis of the shoulder
 (AC), 146–151
 diagnosis, 147–148
 epidemiology, 146
 pathophysiology, 3
 prevalence, 146
 risk factors, 146
 treatment, 148–151
 arthroscopic capsulotomy, 151
 botulinum toxin-A
 injection, 150
 local corticosteroid injection,
 149–150
 manipulation under
 anesthesia, 150
 oral anti-inflammatory
 drugs, 149
 physical therapy, 149
 sodium hyaluronate
 injection, 150
 suprascapular nerve block, 150
- adjunctive therapy
 alternative therapies, 336–344
 cannabidiol (CBD), 349–351
 cognitive therapy, 332–334
 neuromodulation, 319–323
 regenerative medicine, 327–330
see also cannabinoids; cognitive
 behavioral therapy (CBT);
 cognitive functional
 therapy (CFT); discogenic
 low back pain; spinal cord
 stimulation (SCS).
- aging
 as risk factor for CNP, 4
 as risk factor for discogenic low
 back pain, 327
- allodynia
 cannabidiol studies, 16
 as characteristic of CNP, 3
 as characteristic of CPSP, 281
 as characteristic of ON, 88
 CSF1R and, 4
 early post-injury onset as risk
 factor for CNP, 4

- methylprednisolone study, 8
 reduced by CBD, 16
 reduced by essential oils, 5
 reduced by pregabalin, 4
 reduced by TCB-2 treatment, 5
 secondary hyperalgesia and, 236
 vitamin D deficiency and, 27
- alternative therapies, 336–344
 efficacy, 339–343
 epidemiology for chronic pain, 337
 risk factors for chronic pain, 337
 traditional understanding, 338–339
 see also acupuncture; chiropractic;
 osteopathic manipulative
 therapy (OMT); Tai Chi.
- amitriptyline
 for neuropathic pain control, 7
 as treatment for MPS, 268
- amputation, as last resort for CRPS
 patients, 223
- amyloidosis, 109
- anandamide, 14
- ankle/foot pain, 181–188
 diagnosis, 183–185
 epidemiology, 182
 pathophysiology, 182–183
 prevalence, 182
 risk factors, 182
 treatment, 185–188
 Achilles tendinopathy, 186
 CAI, 185
 gout, 187
 Morton's neuroma, 186
 osteoarthritis, 187
 rheumatoid arthritis, 187
 tarsal tunnel syndrome, 186
- antibiotics, impact on gut
 microbiome, 27–28
- anticonvulsants
 contraindications, 64
 dosage/routes of administration, 63
 mechanism(s) of action, 62
 side effects/adverse reactions, 63
 as treatment for cancer pain, 313
 as treatment for migraine
 headache, 79
- as treatment for MS pain, 249
 as treatment for ON, 89
 as treatment for PHN, 215
 as treatment for TN, 84
 as treatment for TOS, 161
- antidepressants
 as strategy to decrease development
 of acute postoperative
 pain, 244
 as treatment for abdominal pain, 291
 as treatment for cancer pain, 313
 as treatment for migraine
 headache, 79
 as treatment for MS pain, 249
 as treatment for TOS, 161
 see also tricyclic antidepressants
 (TCAs).
- antineuropathic medications, 61–64
 contraindications, 64
 dosage/routes of administration,
 62–63
 indications, 62
 mechanism(s) of action, 62
 neuropathic pain, 61–62
 side effects/adverse reactions, 63–64
- arachidonoyl ethanolamide (ADE)
 see anandamide.
- 2-arachidonoylglycerol (2-AG), 15
- arthritic pain
 CBD trials, 19, 351
 CBT as treatment for, 333
- arthritis, as risk factor for CTS, 133
- arthroscopic capsulotomy, as
 treatment for AC, 151
- asthma, diclofenac contraindicated
 for, 51
- baclofen
 intrathecal
 as treatment for CP pain
 and spasticity, 256
 as treatment for CRPS, 223
 as treatment for MS pain, 250
 for neuropathic pain control, 8
 oral, as treatment for pain in CP,
 53–54

Index

- baclofen (cont.)
 and spinal cord stimulation, 323
 balloon sacroplasty (BSP), as
 treatment for SIF, 123
 biofeedback
 as treatment for LBP, 101
 as treatment for MPS, 267
 bisphosphonates
 as treatment for CRPS, 223
 as treatment for osteoporosis,
 111, 123
 bladder pain syndrome (interstitial
 cystitis), 295–296,
 298
 bone marrow aspirate concentrate
 injections, as treatment for
 OA-related pain, 169
 botulinum toxin-A injection
 mechanism of action, 270
 as treatment for AC, 150
 as treatment for CP spasticity and
 pain, 255–256
 as treatment for MPS, 269–270
 as treatment for ON, 90–91
 as treatment for PF, 198
 as treatment for PHN, 215
 as treatment for post-surgical nerve
 entrapment, 305
 as treatment for stroke pain and
 spasticity, 282
 as treatment for TOS, 161
 bowel disorder, unspecified, as cause
 of CAP, 289
 brain
 CBT and, 332
 potential impact of inflammation
 of the pelvic region on, 297
 relationship between gut
 microbiota and, 26
 brain derived neurotrophic factor
 (BDNF), role in CNP, 4
 breast pain, 234–238
 clinical presentation, 237
 diagnosis, 237
 epidemiology, 234–235
 pathophysiology, 236
 post-mastectomy pain
 syndrome, 235
 prevalence of postoperative
 chronic pain, 234
 risk factors, 235
 treatment, 237
 breathing-controlled electrical
 stimulation (BreEStim), for
 neuropathic pain control, 9
 calcitonin, as treatment for VCF, 111
 calcitonin gene-related peptides
 (CGRP), possible role in
 migraine headache, 76
 caloric vestibular stimulation, as
 treatment for CPSP, 284
 cancer
 history of as risk factor for back
 pain, 96
 role of cannabinoid therapy, 19–20
 cancer pain, 308
 chemotherapy-induced peripheral
 neuropathy, 310
 clinical presentation, 310–311
 diagnosis, 310–311
 epidemiology, 308
 evaluation, 311
 pathophysiology, 309–310
 persistent post-surgical pain, 309
 prognosis, 312
 risk factors, 309
 treatment, 312–313
 role of education, 313
 cancer-related pain/nausea,
 cannabinoids indicated
 for, 66
 cannabinoid receptors, activated by
 acetaminophen, 45
 cannabinoids, 66
 analgesic mechanism of action,
 16–17
 CBD, 349–351
 role of in chronic pain
 management, 350–351
 routes of administration,
 349–350

- side effects/adverse reactions, 350
 - as treatment for MS pain, 249
- contraindications, 68
- dosage/routes of administration, 67
- endocannabinoid pathways, 14
- endocannabinoids, 14
- endogenous cannabinoid receptors, 15
- indications, 66
- medications & mechanism(s) of action, 66
- for neuropathic pain control, 7
- pharmacology, 15–16
- side effects/adverse reactions, 67, 250
- therapeutic applications, 18
 - acute pain, 19
 - antiemetic, 19
 - cannabinoid agents, 18
 - chronic pain, 19–20
 - MS, 249
- cannabis, traditional means of ingestion, 18
- capsaicin, 16, 49, 50
 - contraindications, 51
 - dosage/route of administration, 50
 - side effects/adverse reactions, 50
 - as treatment for Morton's neuroma, 186
 - as treatment for PHN, 215
- carpal tunnel syndrome (CTS), 131–140
 - arthritis patients, 133
 - diabetic patients, 133
 - diagnosis, 133–135
 - epidemiology, 131, 132
 - occupations at high risk for development of CTS, 133
 - overuse injury, 133
 - pathophysiology, 132–133
 - prevalence, 131
 - risk factors, 132
 - symptoms, 131, 133
 - treatments, 135–139
 - decompression surgery, 139
 - laser therapy, 139
 - LCI, 139
 - oral anti-inflammatory drugs, 137
 - physical therapy, 136–137
 - PRP, 139
 - ultrasound and shock wave therapy, 137
 - wrist splinting, 135
- celecoxib, as treatment for OA-related pain, 167, 177
- central neuropathic pain (CNP), 3–10
 - altered neuronal cell signaling, 4–5
 - characteristics, 3
 - diagnosis, 5
 - epidemiology, 3
 - non-pharmacologic treatments
 - BreEStim, 9
 - exercise, 10
 - tDCS, 9
 - TMS, 9
 - pathophysiology, 4–5
 - pharmacologic treatments
 - cannabinoids, 7
 - first-line interventions, 6, 7
 - infusions, 8
 - opioids, 7
 - progression, 5
 - risk factors, 4
 - sensitization, 5
 - syndromes included, 3
- central post-stroke pain (CPSP), 279–285
 - CNP and, 3
 - diagnosis, 281
 - epidemiology, 279
 - pathophysiology, 280–281
 - prevalence, 279
 - risk factors, 280
 - treatment, 7, 281–284
- cerebral palsy (CP), 53, 253–258
 - diagnosis, 255
 - epidemiology, 253
 - pathophysiology, 254
 - prevalence, 253
 - risk factors, 253
 - treatment
 - baclofen, 53–54, 256

Index

- cerebral palsy (CP) (cont.)
 botulinum toxin-A,
 255–256
 dantrolene, 56, 256–257
 diazepam, 54, 257
 dorsal rhizotomy, 256
 flexeril, 55, 257
 interventional approaches,
 255–257
 oral muscle relaxants, 53–56
 tizanidine, 55, 257
- cervical disc degeneration, as risk factor for ON, 86
- cervical osteoarthritis, as risk factor for ON, 86
- chemotherapy-induced peripheral neuropathy (CIPN), 310
 as indicator for antineuropathic medication, 62
 trials of treatment with probiotics, 33
- chiropractic
 efficacy, 343
 traditional understanding, 339
- chondroitin, as treatment for OA-related pain, 168, 177
- chronic abdominal pain (CAP), 288–292
 chronic abdominal wall pain (CAWP), 289
 classification, 289
 diagnosis, 290
 epidemiology, 288
 pathophysiology, 289–290
 prevalence, 288–289
 risk factors, 288
 treatment, 291–292
 anesthetic techniques, 291
 interventional approaches, 291
 lifestyle modifications, 292
 pharmacologic, 291
- chronic abdominal wall pain (CAWP), 289
- chronic ankle instability (CAI)
 diagnosis, 183
 pathophysiology, 182
 treatment, 185
- chronic fatigue syndrome (CFS), *see* myalgic encephalomyelitis/chronic fatigue syndrome (CFS).
- chronic gastritis, as cause of CAP, 289
- chronic liver disease, as risk factor for AC, 146
- chronic neuropathic pain,
 cannabinoids *vs* opioids, 20
- chronic pain
 epidemiology, 337
 as leading cause of disability in the world, 337
 microbiome and, *see* microbiome and chronic pain.
 prevalence, 336
 risk factors, 336–337
- chronic pain conditions
 abdominal pain, 288–292
 adhesive capsulitis of the shoulder, 146–151
 ankle/foot pain, 181–188
 breast pain, 234–238
 cancer, 308–313
 carpal tunnel syndrome, 131–140
 complex regional pain syndrome, 220–223
 extremities, 131–140
 head and neck, 69–72
 migraine headaches, 75–79
 miscellaneous, 213–216
 multiple sclerosis pain, 248–250
 myofascial pain syndrome, 261–270
 neuraxial spine pain, 95–103
see also low back pain (LBP).
 OA-related pain, 164–169, 173–178
 occipital neuralgia, 86–91
 pelvic pain, 295–300
 phantom limb pain, 205–209
 plantar fasciitis, 194–200
 post-dural puncture headache, 69–72

- post-herpetic neuralgia, 213–216
- post-stroke pain, 279–285
 - see also* central post-stroke pain (CPSP).
- post-surgical nerve entrapment, 303–305
- post-thoracotomy pain, 240–246
- sacral insufficiency fractures, 119–126
- sickle cell disease, 228–231
- thoracic outlet syndrome, 157–161
- trigeminal neuralgia, 81–84
- vertebral compression fractures, 107–113
 - see also under individual conditions.*
- chronic pelvic pain syndrome (CPPS), 30, 295–300
 - clinical presentation, 298–299
 - diagnosis, 298–299
 - endocrinologic etiology, 297
 - epidemiology, 295–296
 - immunologic etiology, 297
 - infectious etiology, 296
 - mental health impact, 296
 - microbiome and, 30
 - neurologic etiology, 297
 - pathophysiology, 296–297
 - pelvic floor dysfunction
 - etiology, 297
 - treatment, 299–300, 340
- chronic sinusitis, association with TN, 82
- cognitive behavioral therapy (CBT), 332–333
 - access to treatment, 334
 - goals, 332
 - mechanism of effect, 332
 - as treatment for cancer pain, 312
 - as treatment for LBP, 101
 - as treatment for PTSD, 332
 - uses, 333
- cognitive functional therapy (CFT), 333–334
 - access to treatment, 334
 - goals, 333
 - mechanism of effect, 333
 - uses, 334
- colony stimulating factor (CSF1R), role in CNP, 4
- complementary therapies, *see* alternative therapies.
- complex regional pain syndrome (CRPS), 220–223, 320
 - diagnosis, 221
 - diagnosis, Budapest Criteria, 222
 - epidemiology, 220
 - pathophysiology, 220–221
 - risk factors, 220
 - treatment, 9, 222–223
- coronary artery bypass surgery (CABG), comparison with SCS, 321
- coronary artery disease, as risk factor for PTPS, 243
- corticosteroids
 - for neuropathic pain control, 8
 - as treatment for ON, 90
 - see also* local corticosteroid injection (LCI).
- Crohn's disease, as cause of CAP, 289
- cryoneurolysis, as treatment for ON, 90
- dantrolene, as treatment for CP pain and spasticity, 56, 256–257
- decompression surgery, as treatment for CTS, 139
- deep brain stimulation (DBS)
 - as treatment for CPSP, 282
 - as treatment for MS related pain and tremors, 250
 - as treatment for TN, 84, 250
- Dejerine Roussy syndrome, *see* central post-stroke pain (CPSP).
- depression
 - association with migraine headaches, 75
 - CPPS and, 296–298
 - microbiota depletion and, 27

Index

- depression (cont.)
 relationship with chronic pain, 17, 27, 337
 as risk factor for CRPS, 220
 as risk factor for MPS, 261
- diabetes
 association with TN, 82
 as protective factor for CRPS, 220
 relationship with adhesive capsulitis, 146
 as risk factor for CTS, 132–133
 as risk factor for gout, 182
 as risk factor for ON, 86
 as risk factor for PHN, 213
 as risk factor for PTPS, 243
- diabetic neuropathy, as indicator for antineuropathic medication, 62
- diazepam, as treatment for CP pain and spasticity, 54, 257
- diclofenac
 contraindications, 51
 dosage/route of administration, 50
 side effects/adverse reactions, 50–51
- diet, socioeconomic perspective, 26
- dietary interventions for chronic pain, 33–34
- differentially expressed genes, as risk factor for CNP, 4
- diffusion tensor tractography, as treatment for CPSP, 284
- discogenic low back pain, 327–330
 epidemiology, 327
 pathophysiology, 327–328
 risk factors, 327
 treatment, 328–330
 platelet rich plasma, 329–330
 stem cell therapy, 328–329
see also low back pain (LBP).
- dorsal rhizotomy, as treatment for CP pain and spasticity, 256
- dorsal root ganglion stimulation (DRG-S), 319
 as treatment for LBP, 103
 as treatment for PLP, 208
 as treatment for PTPS, 245
- dronabinol, as treatment for gastrointestinal distress in cancer patients, 19
- dry needling (DN), as treatment for MPS, 265
- duloxetine, 62, 100
 mechanism of action, 62
 for neuropathic pain control, 7
 side effects/adverse reactions, 63–64
 as treatment for LBP, 100
- duodenal ulcers, as cause of CAP, 289
- Dupuytren's disease, as risk factor for AC, 146
- dural puncture during epidural or spinal anesthesia, common adverse complications following, 69, *see also* post-dural puncture headache (PDHP)
- dysaesthesia
 as characteristic of CPSP, 281
 as characteristic of ON, 88
- dysbiosis
 disease states associated with, 26
 income inequality and, 26
 opioids and, 28
 proposed treatments, 34
 relationship with osteoarthritis, 29
 role of infection, 28
- embryonic stem cells (ESC),
 disadvantages of treatment with, 328
- endocannabinoid pathways, vitamin D deficiency and, 27
- endocannabinoids, 14
- endogenous cannabinoid receptors, 15
- epidiolex
 dosage/routes of administration, 67
 side effects/adverse reactions, 67
- epidural anesthesia, common adverse complications following, 69, *see also* post-dural puncture headache (PDHP); post-

- dural puncture headache (PDPH)
- epidural blood patch (EBP)
 - potential complications, 72
 - as treatment for PDPH, 71–72
- epidural steroid injections, as treatment for LBP, 102
- epilepsy
 - association with migraine headaches, 75
 - TMS contraindicated in patients with, 78
- epitriptan, as treatment for SCD pain crises, 230
- exercise
 - for neuropathic pain control, 10
 - as treatment for CAP, 292
 - as treatment for OA-related pain, 167, 176–177
 - as treatment for PF, 197
 - as treatment for VCF, 111
- extracorporeal shock wave therapy (ESWT), 199
 - CTS trials, 137
 - PF trials, 199
- failed back surgery syndrome (FBSS),
 - SCS as treatment for, 320
- fecal transplantation, 28, 33
- female gender
 - association with chronic pain conditions, 69, 146, 164, 173–174, 182, 213, 337
 - see also* women.
- fentanyl, as treatment for SCD pain crises, 230
- fermented foods, benefits for the gut biome, 33
- fibromyalgia
 - acupuncture trials, 340
 - association with CPPS, 30
 - cannabinoid therapy, 20
 - CBT as treatment for, 333
 - diagnosis, 31
 - distinguishing from MPS, 264
 - potential benefits of dietary interventions, 33
 - probiotics trials, 32
 - relationship with microbiome, 30–31
 - Tai Chi trials, 342
 - TMS as treatment for, 9
- flexeril, as treatment for CP pain and spasticity, 55, 257
- Fothergill's Disease, *see* trigeminal neuralgia (TN).
- frozen shoulder, 146 *see* adhesive capsulitis of the shoulder (AC).
- functional gastrointestinal disorders (FGIDs), as cause of CAP, 289
- GABA-ergic neurotransmitters, role in CNP, 4
- gabapentin
 - contraindications, 64
 - dosage/routes of administration, 63
 - mechanism of action, 62
 - for neuropathic pain control, 6
 - side effects/adverse reactions, 63–64
 - as treatment for breast pain, 237
 - as treatment for LBP, 101
 - as treatment for PTPS, 245
- gastric ulcers, as cause of CAP, 289
- gastroesophageal reflux disease (GERD), as cause of CAP, 289
- glucosamine as treatment for OA-related pain, 168, 177
- gout
 - diagnosis, 184
 - pathophysiology, 183
 - as risk factor for ON, 86
 - risk factors, 182
 - treatment, 187
- greater occipital nerve (GON), 86, *see also* occipital neuralgia (ON)

Index

- gut flora
 - benefits of diversity, 27–28
 - opioids and dysregulation of, 28–29
 - potential role of dysbiosis in osteoarthritis, 29
- gut-brain axis, and neurobehavioral development, 26
- head trauma, as risk factor for ON, 86
- heart conditions, lidocaine
 - contraindicated for, 51
- hepatic disease, diclofenac
 - contraindicated for, 51
- hepatotoxicity, symptoms, 46
- HIV-associated weight loss,
 - cannabinoids indicated for, 66–67
- hormone dysregulation, as risk factor for VCF, 108
- hyaluronic acid injection
 - as treatment for Morton's neuroma, 186
 - as treatment for OA-related pain, 168–169, 187
 - see also* sodium hyaluronate.
- hydroxyurea, as treatment for SCD pain crises, 230
- hyperlipidemia, as risk factor for AC, 146
- hypertension, as risk factor for PTPS, 243
- hyperthyroidism, as risk factor for AC, 146
- hypothyroidism
 - as protective factor for CRPS, 220
 - as risk factor for CTS, 132
- imaging
 - CRPS, 221
 - for diagnosis of CAP, 290
 - for diagnosis of CNP, 6
 - for diagnosis of CPSP, 281
 - for diagnosis of LBP, 98
 - for diagnosis of SIF, 121
 - for diagnosis of TN, 82–83, 84
- role in determining etiology of ON, 89
- immunoglobulin therapy, as treatment for CRPS, 223
- income, relationship with chronic pain, 337
- inflammatory bowel disease (IBD), association with CPPS, 30
- infusions, for neuropathic pain control, 8
- insomnia, as risk factor for MPS, 261
- interferential current therapy (IFC), as treatment for MPS, 266
- International Association for the Study of Pain (IASP), 5, 61, 221, 240, 288, 311
 - definition of pain, 288
- International Classification of Headache Disorder (ICHD-III), 76, 88
- International Headache Society (IHS), 83
- interstitial cystitis (bladder pain syndrome), 295–296, 298
- intestinal permeability, potential relationship with chronic pain, 28
- intrathecal baclofen, as treatment for CP pain and spasticity, 256
- irritable bowel syndrome (IBS)
 - benefits of exercise, 292
 - as cause of CAP, 289
- juvenile idiopathic arthritis, microbiome research and, 30
- ketamine
 - as treatment for CRPS, 223
 - as treatment for PTPS, 245
 - as treatment for SCD pain crises, 230
- kyphoplasty, as treatment for VCF, 112

- lamotrigine, for neuropathic pain control, 7
- laser therapy, as treatment for CTS, 139
- “leaky gut” hypothesis, 28
- lesser occipital nerve (LON), 86, *see also* occipital neuralgia (ON)
- lidocaine
contraindications, 51
dosage/route of administration, 50
mechanism of action, 49
side effects/adverse reactions, 50
as treatment for MPS, 269–270
- lidocaine injection therapy, as treatment for MPS, 269
- lidocaine patches
as treatment for SCD pain crises, 230
as treatment for VCF, 111
- local anesthetic
as treatment for Morton’s neuroma, 186
as treatment for PF, 198
- local corticosteroid injection (LCI)
CTS studies, 139
as treatment for AC, 149–150
as treatment for gout-related pain, 187
as treatment for MPS, 269–270
as treatment for OA-related pain, 168, 177, 187
as treatment for PF, 198
as treatment for rheumatoid arthritis pain, 187
- local injections, as treatment for MPS, 269–270
- low back pain (LBP), 342
acupuncture trials, 339
CFT as treatment for, 334
chiropractic trials, 343
clinical presentation, 95
cost, 119
diagnostic testing, 97
imaging, 98
interventions, 102–103
OMT trials, 339
pharmacologic treatments, 100–101
physical and rehabilitation treatments, 101
physical examination, 96–97
prevalence, 95, 119
psychological treatments, 101
relationship with opioid-related deaths, 119
surgery-related, 320
Tai Chi trials, 342
see also discogenic low back pain; neuraxial spine pain.
- lumbar support, as treatment for LBP, 102
- magnetic resonance elastography (MRE), in diagnosis of MPS, 263
- malignancy, as risk factor for SIF, 120
- marinol
dosage/routes of administration, 66–67
side effects/adverse reactions, 67
- massage
as treatment for cancer pain, 312
as treatment for LBP, 102
- mastectomy, as risk factor for AC, 146
- menopause
and impact of lack of estrogen, 108
as risk factor for CRPS, 220
as risk factor for CTS, 132
as risk factor for SIF, 120
- mesenchymal stem cells (MSC), as treatment for OA-related pain, 169, 178, 187
- metabolic bone disorders, as risk factor for SIF, 120
- methotrexate, as treatment for rheumatoid arthritis pain, 188

Index

- methylprednisolone, for neuropathic pain control, 8
- microbiome and chronic pain, 26–34
 - the microbiome, 26
 - clinical evidence, 30–32
 - chronic pelvic pain syndrome (CPPS), 30
 - fibromyalgia, 30–31
 - myalgic encephalomyelitis/chronic fatigue syndrome (CFS), 31–32
 - current research and recommendations, 34
 - experimental evidence, 27–29
 - diversity of gut flora, 27–28
 - infection, 28
 - opioids, 28–29
 - osteoarthritis, 29
 - vitamin D, 27
 - treatments, 32–34
 - dietary interventions, 33–34
 - probiotics, 32–33
- migraine
 - acupuncture trials, 341
 - association with gastrointestinal disorders, 32
 - CBD trials, 351
 - CBT as treatment for, 333
 - chiropractic trials, 343
 - efficacy of cannabinoids in the treatment of, 20
 - OMT trials, 343
 - probiotics trials, 33
- migraine headaches, 75–79
 - associated conditions, 75
 - characteristics, 75
 - diagnosis, 76–77
 - epidemiology, 75–76
 - genetic/epigenetic factors, 76
 - pathophysiology, 76
 - prevalence, 75
 - risk factors, 75–76
 - treatment, 77–79
 - two categories, 76
- miRNAs, as risk factor for CNP, 4
- mirror therapy, as treatment for CPSP, 284
- Morton's neuroma
 - diagnosis, 184
 - pathophysiology, 182
 - risk factors, 182
 - treatment, 186
- motor cortex stimulation (MCS), 282–283
 - as treatment for CPSP, 283
- motor cortex stimulation, as potential treatment for TN, 84
- multiple sclerosis (MS), 20, 248–250
 - association with migraine headaches, 75
 - association with ON, 87
 - association with TN, 82
 - benefits of exercise, 250
 - benefits of physical therapy, 250
 - cannabinoids indicated for, 66
 - clinical presentation, 248
 - comparison with CPSP, 281
 - DBS as treatment for pain and tremors, 250
 - diagnosis, 248
 - headaches, 249
 - inclusion under CNP, 3
 - intrathecal baclofen pump with electrical stimulation, 250
 - management of associated spasticity, 55, 56
 - neuromodulation, 250
 - neuropathic pain, 249
 - pathophysiology, 248
 - role of cannabinoid therapy, 40
 - Tai Chi trials, 342
 - TN and, 248–249
 - treatment, 249–250
- muscle relaxants
 - as treatment for MPS, 268
 - as treatment for TOS, 161
 - as treatment for VCF, 111
- myalgic encephalomyelitis/chronic fatigue syndrome (CFS), 31
 - microbiome and, 31–32

- potential benefits of dietary interventions, 33
- symptoms, 20
- myeloma, as risk factor
for VCF, 108
- myofascial pain syndrome (MPS),
261–270
- diagnosis, 263–264
- epidemiology, 261
- pathophysiology, 262–263
- prevalence in patients with other
types of pain disorders,
263–264
- risk factors, 261
- treatment
- acupuncture, 265–266
 - biofeedback, 267
 - clinical interventions
comparison, 270
 - commonly used drugs, 270
 - dry needling, 265
 - interferential current
therapy, 266
 - interventional approaches,
269–270
 - local injections, 269–270
 - muscle relaxants, 268
 - myofascial release, 264–265
 - non-pharmacologic, 264–267
 - NSAIDs, 267–268
 - pharmacologic, 267–269
 - TCAs, 268
 - TENS, 266
 - tizanidine, 269
- myofascial release (MFR), as
treatment for MPS,
264–265
- nabilone
- dosage/routes of administration,
67
 - side effects/adverse reactions, 67
 - as treatment for gastrointestinal
distress in cancer
patients, 19
- nabiximols, 66
- approved as treatment for opioid-
resistant cancer pain, 20
- dosage/routes of administration, 67
- side effects/adverse reactions, 67
- naltrexone, as treatment for MS
pain, 249
- N-arachidonoyldopamine
(NADA), 15
- natural anti-inflammatory and
anti-oxidative substances
(NAIOs), examples of, 34
- neck pain, CFT as treatment for, 334
- neck strain, as risk factor for ON, 87
- nerve block, as treatment for
PHN, 216
- neuraxial spine pain, 95–103
- clinical presentation, 95–97
 - diagnostic testing, 97–98
 - etiology, 98–99
 - motion tests, 97
 - treatment, 100–103
 - see also* low back pain (LBP).
- neurectomy, as treatment for
Morton's neuroma, 186
- neurobehavioral development,
gut-brain axis and, 26
- neuromodulation, 319–323
- cost-effectiveness, 320
 - indications, 320–321
 - patient selection, 321
 - technical considerations, 322–323
 - as treatment for CPSP, 283
 - as treatment for MS-related
symptoms, 250
 - as treatment for ON, 90
 - trial periods, 321–322
 - see also* spinal cord
stimulation (SCS).
- neuropathic pain (NP)
- acupuncture trials, 341
 - etiologies/classification, 61–62
 - mechanism(s) of action, 62
 - medications, 62
 - MS-related, 249
 - see also* antineuropathic
medications.

Index

- noladin ether, 15
- nonsteroidal anti-inflammatory drugs (NSAIDs), 39
- contraindications, 41
 - dosage, 40
 - indications, 39
 - list of medications, 39
 - mechanism(s) of action, 40
 - metabolism, 41
 - potential impact on bone mineral density, 123
 - routes of administration, 40
 - side effects/adverse reactions, 41
 - as treatment for AC, 149
 - as treatment for breast pain, 237
 - as treatment for LBP, 100
 - as treatment for migraine headaches, 77
 - as treatment for MPS, 267–268
 - as treatment for OA-related pain, 167, 177, 187
 - as treatment for PDPH, 71
 - as treatment for PF, 198
 - as treatment for SCD pain crises, 230
 - as treatment for SIF, 123
 - as treatment for TOS, 161
 - as treatment for VCF, 111
 - not useful as treatment for CTS, 137
- obesity
- as protective factor for CRPS, 220
 - as protective factor for PDPH, 70
 - as risk factor for AC, 146
 - as risk factor for ankle/foot pain, 182
 - as risk factor for chronic pain, 337
 - as risk factor for CTS, 132
 - as risk factor for discogenic back pain, 327
 - as risk factor for OA-related pain, 165
 - as risk factor for PF, 195
 - as risk factor for PTPS, 243
 - as risk factor for VCF, 108
 - role in osteoarthritis, 29
- occipital neuralgia (ON), 86–91
- characteristics, 86
 - diagnosis, 88–89
 - epidemiology, 86
 - etiology, 87
 - incidence rate, 86
 - pathophysiology, 86, 87–88
 - refractory, 91
 - risk factors, 86
 - role of imaging, 89
 - treatment, 89–91
- oligofructose supplementation, potential benefits for OA-related degeneration, 29
- opiates, 58
- opioids, 58
- CBD as potential alternative, 351
 - contraindications, 60
 - full and partial agonists, 58
 - and gut flora dysregulation, 28–29
 - indications, 59
 - mechanism(s) of action, 59
 - metabolism, 59
 - for neuropathic pain control, 7
 - opiate antagonists, 59
 - prevalence of abuse, 336
 - risks of, 112, 119, 168, 177, 238
 - side effects/adverse reactions, 59
 - as treatment for breast pain, 238
 - as treatment for cancer pain, 312
 - as treatment for LBP, 100
 - as treatment for OA-related pain, 167, 177
 - as treatment for PHN, 215
 - as treatment for SCD pain crises, 230
 - as treatment for TOS, 161
 - as treatment for VCF, 111
- oral corticosteroids, as treatment for PF, 198
- osteoarthritic hip pain, 164–169
- diagnosis, 165–167
 - epidemiology, 164
 - pathophysiology, 165

- prevalence, 164
- risk factors, 165
- treatment, 167–169
 - exercise, 167
 - local injections
 - corticosteroid injections, 168
 - other intraarticular injections, 168–169
 - oral medications, 167–168
 - weight loss, 167
- osteoarthritic knee pain, 173–178
 - diagnosis, 174–176
 - epidemiology, 173
 - pathophysiology, 174
 - prevalence, 174
 - risk factors, 174
 - treatment, 176–178
 - exercise, 176–177
 - local injections
 - corticosteroid injections, 177
 - other intraarticular injections, 178
 - oral medications, 177
 - Tai Chi as an intervention for improving functionality, 342
 - weight loss, 176
- osteoarthritis (OA)
 - ankle/foot pain treatment, 187
 - association with MTrPs, 264
 - association with neuraxial spine pain, 98
 - diagnosis, 184
 - pathophysiology, 183
 - potential role of gut dysbiosis, 29
 - as risk factor for ankle/foot pain, 182
 - role of obesity, 29
 - Tai Chi trials, 342
 - see also* osteoarthritic hip pain; osteoarthritic knee pain.
- osteopathic manipulative therapy (OMT)
 - efficacy, 342–343
 - traditional understanding, 338
- osteoporosis
 - as risk factor for SIF, 120
 - as risk factor for VCF, 107
 - osteoporotic fractures, most common type, 107
- Oswestry Disability Index (ODI), 124
- Paget-von Schroetter syndrome (venous TOS), 159
- pain, IASP definition, 288
- Parkinson's disease, Tai Chi trials, 342
- pectoral blocks, as treatment for breast pain, 238
- pelvic pain, 295–300
 - see also* chronic pelvic pain syndrome (CPPS)
- peripheral nerve stimulation (PNS), 245, 319
- peripheral neuropathic pain
 - cannabinoids indicated for, 66–67
 - TMS as treatment for, 9
- persistent post-surgical pain (PPSP), cancer pain, 309
- phantom limb pain (PLP), 205–209
 - cortical remapping theory, 206
 - diagnosis, 206–207
 - epidemiology, 205
 - as indicator for antineuropathic medication, 62
 - neuromatrix theory, 206
 - pathophysiology, 206
 - prevalence post-amputation, 205
 - proprioceptive memory theory, 206
 - risk factors, 205
 - treatment, 207–208
 - DRG stimulation, 208
 - gabapentin, 208
 - ketamine infusion, 208
 - mirror therapy, 207
 - opioids, 208
 - psychiatric, 207
 - spinal cord stimulation, 208
 - TMS, 208
 - types of sensation, 207
- physical therapy, as treatment for CRPS, 222

Index

- plantar fasciitis (PF), 194–200
 diagnosis, 195–196
 epidemiology, 194
 healthcare spending burden, 194
 pathophysiology, 195
 prevalence, 194
 risk factors, 195
 treatment, 196–199
 botulinum toxin-A injection, 198
 ESWT, 199
 LCI, 198
 oral anti-inflammatory drugs, 198
 orthotics, 198
 PRP injections, 198
 radiofrequency ablation, 199
 strengthening exercises, 197
 stretching, 197
 weight loss, 196
- platelet-rich plasma (PRP)
 advantages, 329–330
 research recommendations, 330
 route of administration, 330
 as treatment for Achilles tendinopathy, 186
 as treatment for CAI, 185
 as treatment for CTS, 139
 as treatment for OA-related pain, 169, 178, 187
 as treatment for PF, 198
- post-dural puncture headache (PDPH), 69–72
 characteristics, 69
 diagnosis, 70
 epidemiology, 69
 pathophysiology, 147
 risk factors, 107
 treatment, 70–72
- post-herpetic neuralgia (PHN), 213–216
 diagnosis, 214
 epidemiology, 213
 as indicator for antineuropathic medication, 62
 pathophysiology, 213
 risk factors, 213
 treatment, 214–216
- post-operative nausea and vomiting (PONV), cannabinoid therapy, 19
- post-surgical nerve entrapment, 303–305
 clinical presentation, 303
 diagnosis, 304
 epidemiology, 303
 pathophysiology, 303
 treatment, 17
- post-thoracotomy pain syndrome (PTPS), 240–246
 diagnosis, 243
 epidemiology, 241
 pathophysiology, 241–242
 prevalence/incidence, 241
 risk factors, 241, 243
 treatment and prevention
 anesthetic techniques, 244
 interventional treatment, 245
 pharmacologic treatment, 245
 surgical techniques, 244
- post-traumatic stress disorder (PTSD)
 association with migraine headaches, 75
 CBT as treatment for, 332
 as risk factor for MPS, 261
 prefrontal cortex, association with pain, 333
- pregabalin
 contraindications, 64
 dosage/routes of administration, 63
 mechanism of action, 62
 for neuropathic pain control, 6
 side effects/adverse reactions, 63–64
 as treatment for breast pain, 237
 as treatment for CNP, 6
 as treatment for LBP, 101
 as treatment for PTPS, 245
- pregnancy
 acupuncture trials for treatment of pelvic and labor pain, 340
 lidocaine contraindicated for, 51
 NSAIDs contraindicated for, 41

- OMT trials for pregnancy-related low back pain, 342
- opioids contraindicated for, 60
- as risk factor for CTS, 132
- as risk factor for PDPH, 69
- as risk factor for SIF, 120
- transient bone weakening, 109
- prevotella, CPPS and, 30
- probiotics, for treatment of chronic pain, 32–33
- progressive relaxation, as treatment for LBP, 101
- prolotherapy injections, as treatment for Achilles tendinopathy, 186
- prostatitis, 295–297, 340
- pulsed radiofrequency, as treatment for ON, 91
- qigong, 341
- radiation exposure, as risk factor for VCF, 108
- radiofrequency ablation (RGA)
- as treatment for ON, 90
 - as treatment for PF, 199
- radiofrequency sacroplasty (RFS), as treatment for SIF, 125
- RANK ligand inhibitors, 111, 113
- regenerative medicine, 327–330, *see also* discogenic low back pain
- restless leg syndrome, association with migraine headaches, 75
- retractable anginal pectoris (RAP), SCS as treatment for, 320–321
- rheumatoid arthritis
- ankle/foot pain treatment, 187
 - diagnosis, 185
 - microbiome research and, 30
 - pathophysiology, 183
 - as risk factor for ankle/foot pain, 182
 - as risk factor for SIF, 120
 - Tai Chi trials, 342
- sacral insufficiency fractures (SIF), 119–126
- diagnosis
- approach to, 121
 - Denis classification, 122
 - imaging, 121
 - presentation, 120–121
- epidemiology, 119
- pathophysiology, 120
- risk factors, 120
- treatment
- conservative management, 122–123
 - minimally invasive management, 123–125
 - surgical management, 125
 - see also* low back pain (LBP).
- sacroiliac joint interventions, as treatment for LBP, 102
- sacroplasty, as treatment for SIF, 123–125
- sativex, side effects/adverse reactions, 67
- serotonin-noradrenaline reuptake inhibitors (SNRIs), 6, 62, 64
- contraindications, 41
- side effects/adverse reactions, 63–64
- as treatment for LBP, 100
- Shingles, 214, *see also* post herpetic neuralgia (PHN)
- sickle cell disease (SCD), 228–231
- diagnosis, 229–230
- epidemiology, 229
- most common locations of chronic pain, 228
- pathophysiology, 229
- prevalence, 229
- risk factors, 229
- sickle cell acute pain crisis, 228
- treatment, 230
- adjunctive pharmaceutical analgesic for vasoocclusive crisis, 231
 - non-pharmaceutical management of pain, 232

Index

- smoking, as risk factor for discogenic low back pain, 327
- sodium hyaluronate
as treatment for AC, 150
as treatment for OA-related pain, 178, *see also* hyaluronic acid injection.
- soluble fiber, potential role in immunologic functioning, 26
- spasticity
effects of cannabinoids on, 20
in MS, 249
interventional approaches for pain and, 255–257
- spinal anesthesia, common adverse complications following, 69, *see also* post-dural puncture headache (PDHP); post-dural puncture headache (PDPH)
- spinal cord injury (SCI), 3
benefits of exercise for, 10
as indicator for antineuropathic medication, 62
management of associated spasticity, 55
post-SCI pain, 5, 6–8, 9, 10
role in CNP, 4–5
- spinal cord stimulation (SCS)
baclofen and, 323
contraindications, 321
efficacy, 320
goal of, 323
mechanism of action, 319
minimizing risk of habituation, 323
opioid use and, 323
patient selection, 321
technical considerations, 322–323
as treatment for abdominal pain, 291
as treatment for CRPS, 223, 320
as treatment for LBP, 102
as treatment for pain in MS, 249–250
as treatment for persistent PTPS, 245
trialing, 321–322
- spinal metastasis, as risk factor for VCF, 108
- spinal misalignment, as risk factor for VCF, 107
- stellate ganglion block, as treatment for CPSP, 284
- stem cell therapy, 328–329
advantages and disadvantages, 328–329
research recommendations, 329
route of administration, 329
types of stem cells, 328
- Stevens-Johnson syndrome, 46, 63
- stroke, association with migraine headaches, 75
- suprascapular nerve block, as treatment for AC, 150
- surgical decompression, as treatment for refractory ON, 91
- systemic lupus erythematosus, association with migraine headaches, 75
- Tai Chi
efficacy, 341–342
traditional understanding, 338
- tarsal tunnel syndrome
diagnosis, 184
pathophysiology, 183
risk factors, 182
treatment, 186
- teriparatide, as treatment for SIF, 123
- tetrahydrocannabinol (THC), 18–21, 66–67, 349
- thalamic pain syndrome, *see* central post-stroke pain (CPSP).
- third occipital nerve (TON), 86, *see also* occipital neuralgia (ON)
- thoracic outlet syndrome (TOS), 157–161
anatomy & etiology, 157–159
clinical presentation, 159–160

- diagnosis, 160
epidemiology, 157
management, 161
symptoms, 157
- tic douloureux, *see* trigeminal neuralgia (TN).
- tizanidine
as treatment for CP pain and spasticity, 55, 257
as treatment for MPS, 269
- toll-like receptors (TLRs), and opioid-related dysbiosis, 28
- topical administration of medication, 49–51
indications, 49
see also capsaicin; diclofenac; lidocaine.
- topiramate, as treatment for LBP, 101
- tramadol
as treatment for OA-related pain, 167, 177
as treatment for PHN, 215
- transcranial direct current stimulation (tDCS)
for neuropathic pain control, 9
as treatment for CPSP, 283
- transcranial magnetic stimulation (TMS)
in diagnosis of MPS, 263
for neuropathic pain control, 9
potential for mitigation of MS symptoms, 250
as treatment for CPSP, 282–283
- transcranial stimulation, as treatment for CPSP, 282
- transcutaneous electrical nerve stimulation (TENS)
as treatment for LBP, 102, 266–267
as treatment for MPS, 266
as treatment for PHN, 215
- tricyclic antidepressants (TCAs)
contraindications, 64
dosage/routes of administration, 63
mechanism of action, 62
side effects/adverse reactions, 63–64
as treatment for LBP, 100
as treatment for MPS, 268
as treatment for ON, 89
as treatment for PHN, 215
as treatment for TN, 84
- trigeminal neuralgia (TN), 81–84
characteristics, 81, 83
diagnosis, 83–84
epidemiology, 81–82
imaging tests and alternatives, 82–83, 84
as indicator for antineuropathic medication, 62
MS-related, 248–249
pathophysiology, 82–83
prevalence, 81
risk factors, 81–82
treatment, 84
- ulcers, gastric and duodenal, as cause of CAP, 289
- urticaria, diclofenac contraindicated for, 51
- vaccines, for prevention of Shingles rash, 214
- venlafaxine
dosage/routes of administration, 62
mechanism of action, 62
side effects/adverse reactions, 63–64
as treatment for LBP, 100
- vertebral compression fractures (VCFs), 107–113
atypical light chain amyloidosis, 109
diagnosis, 109–111
epidemiology, 107
gestation, 109
low estrogen effects, 108
osteoporosis, 108
pathophysiology, 108
risk factors, 107
treatment
conservative, 111
research and guidelines, 112–113

Index

- VCFs (cont.)
vertebral augmentation, 112
- vertebroplasty, as treatment for
VCF, 112
- vertebroplasty/kyphoplasty, as risk
factor for VCF, 107
- vestibulodynia, 295–296
- virodhamine, 15
- vitamin C, as treatment for
CRPS, 223
- vitamin D, potential role in pain
development, 27
- vitamin D deficiency, as risk factor
for MPS, 261
- whiplash injuries, as risk factor
for ON, 87
- women
abdominal pain, 288
CPPS, 295–296
CRPS, 220
migraine headaches, 75
ON, 86
PF, 194
TOS, 157
VCFs, 107, 111
- yoga, potential benefits
CAP patients, 292
chronic pain sufferers, 341
MS patients, 250
- ziconotide, for neuropathic pain
control, 8